NASDAQ:HUMAW Humacyte (HUMAW) Stock Forecast, Price & News $0.99 -0.01 (-1.00%) (As of 06/7/2023 ET) Add Share Share Today's Range$0.89▼$0.9950-Day Range$0.50▼$1.0452-Week Range$0.38▼$1.53Volume204 shsAverage Volume13,199 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Receive HUMAW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter. Email Address HUMAW Stock News HeadlinesMay 30, 2023 | americanbankingnews.comHumacyte, Inc. (NASDAQ:HUMAW) Sees Large Growth in Short InterestApril 19, 2023 | americanbankingnews.comShort Interest in Humacyte, Inc. (NASDAQ:HUMAW) Expands By 42.2%June 8, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.March 30, 2023 | americanbankingnews.comHumacyte, Inc. (NASDAQ:HUMAW) Sees Significant Growth in Short InterestSee More Headlines HUMAW Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Industry, Sector and Symbol Stock ExchangeNASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:HUMAW CUSIPN/A CIK1818382 WebN/A PhoneN/AFaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Institutional OwnershipCVI Holdings LLCSold 35,040 shares on 5/16/2023Ownership: 0.000%Sio Capital Management LLCBought 49,998 shares on 5/15/2023Ownership: 0.000%View All Institutional Transactions HUMAW Stock - Frequently Asked Questions How have HUMAW shares performed in 2023? Humacyte's stock was trading at $0.3926 at the start of the year. Since then, HUMAW shares have increased by 152.2% and is now trading at $0.99. View the best growth stocks for 2023 here. Are investors shorting Humacyte? Humacyte saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 11,700 shares, an increase of 7.3% from the April 30th total of 10,900 shares. Based on an average trading volume of 13,100 shares, the short-interest ratio is currently 0.9 days. View Humacyte's Short Interest. What is Humacyte's stock symbol? Humacyte trades on the NASDAQ under the ticker symbol "HUMAW." Who are Humacyte's major shareholders? Humacyte's stock is owned by many different retail and institutional investors. Top institutional investors include CVI Holdings LLC (0.00%) and Sio Capital Management LLC (0.00%). How do I buy shares of Humacyte? Shares of HUMAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Humacyte's stock price today? One share of HUMAW stock can currently be purchased for approximately $0.99. This page (NASDAQ:HUMAW) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.